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In the last decades, many researchers aimed to identify causal genetic variants by means of candidate
gene analyses, genome wide linkage and association studies to elucidate underlying mechanisms of
osteoarthritis (OA). Although several consistent genetic variants were identiﬁed the successes are
limited. This review has a focus on studies published until mid 2011 and on data presented at the
Osteoarthritis Research Society International 2011 (OARSI) in San Diego and that aim to elucidate the
primary molecular and cellular events commencing OA onset in humans by applying genetic study
designs.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
As outlined in 2010 genetic ‘year in a review’ there are major
impediments that hamper the detection of robust genetic signals in
complex diseases such as osteoarthritis (OA): (1) The considerable
genetic component in OA is most likely of a polygenic nature with
modest effect sizes1 which inevitably implies a comprehensive
collaborative approach involving many cases and controls. (2) The
large heterogeneity of the OA phenotype; occurring at speciﬁc joint
locations, in a more generalized form or with and without clinical
presentation each with their own heritability estimate. Further-
more, also in genetic studies there is lack of consensus on case and
control deﬁnitions leading to misclassiﬁcation within case and/or
control groups and therewith a reduction of power.
Despite these culprits, genetic studies up until now have
provided a few compelling signals such as the 7q22 locus2 con-
taining multiple potential genes, the growth differentiation factor
5 (GDF5) gene3,4, frizzled related protein (FRZB) gene5, the deiodi-
nase, iodothyronine, type II (DIO2) gene6 and the SMAD3 gene7 (see
also Table I). These signals have been discovered by a combination
of (discovery driven) genome wide scans and hypotheses driven
candidate gene approaches. The latter depends on an educated
guess in understanding the biological pathways leading to disease.
Furthermore, it should be noted that the applied analyses (linkage
and/or association) are depending on the expected penetrance of
the gene variant and its frequency. When the expected penetrance
is moderate to large, the variant frequency relative lowand possiblyI. Meulenbelt, Department of
ter, Einthovenweg20, POBox
-9734; Fax: 31-71-526-8280.
s Research Society International. Pheterogenic, linkage analyses are considered most appropriate.
However, when the underlying rationale has a focus on the
‘common disease, common variant’ hypothesis, a genome wide
association (GWA) study is most appropriate. It should be noted
that because of this essential difference of the nature of the signal,
the genes found through linkage are not necessarily replicated in
GWA scans and vice versa (e.g., the FRZB gene5,8). This does not
directly discard the initial results but merely reﬂects the fact that
the different approaches are best suited to capture susceptibility
genes from different ends of the complex genetic spectrum. The
results depicted in Table I represent a typical mixture of such
genetic ﬁndings reported up until 2010.
At present, only two OA susceptibility signals (GDF5 and 7q22)
meet the strict international criteria of genome wide signiﬁcance,
set at a P-value below 5108. The 7q22 locus contains six genes in
a linkage disequilibrium block extending over 500 kb, none of
which appeared as obvious OA candidate. On the other hand, the
encoded protein of the GDF5 gene is a member of the bone
morphogenetic protein (BMP) family and the TGF-beta super family.
The role of GDF5 in the development and maintenance of bone and
cartilage has been known for some time, however, the exact
mechanism by which the recognized susceptibility single nucleo-
tide polymorphism (SNP) rs143383 and rs143384 confer risk to OA
remains to be elucidated. Such results present the typical problems
that occur in the mapping of complex traits and expose the gap
between genetic evidence and the molecular mechanism behind
the disease. Now that several large consortia (such as TREATwOA
arcOGEN) have been piling up GWAs data on OA to perform
powerful meta-analyses and thus the discovery of additional robust
OA associated SNPs with the expected small effect sizes is
assured9e12, the need for functional pipelines to elucidate the
underlying mechanism becomes imperative.ublished by Elsevier Ltd. All rights reserved.
Table I
A selection of previous OA susceptibility loci (up until 2010) discovered by
a combination of genome wide linkage, GWA and candidate gene approaches
Phenotype Pathway involved Reference
Genome wide linkage
FRZB Hip OA WNT signaling 5
DIO2 GOA; Hip OA Thyroid signaling 6
Candidate gene
GDF5 Hip OA TGF-beta signaling 3
SMAD3 Hip OA TGF-beta signaling 7
GWA
Chrom 7q22; COG5, GPR22 Knee OA e 2
HLA Class II/III Knee OA Immunology 20
GOA¼ generalized OA.
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the clinical heterogeneity, to conduct additional powerful GWA
scans with over 7,000 cases and controls and to perform functional
follow up of current OA susceptibility loci to identify the underlying
mechanisms. The following selection of subjects is based on the
opinion of the author and has a focus on the discovery of genetic
signals in OA etiology.
Phenotype heterogeneity
As indicated phenotypic heterogeneity in OA and the lack on
consensus on case and control deﬁnition is considerably diluting
power in GWA studies due to misclassiﬁcation. In 2011, Kerkhof
et al.13 have attempted to minimize the differences in OA case and
control deﬁnitions by putting forward, recommendations for
standardization and phenotype deﬁnitions in genetic studies of OA.
Applying stricter selection criteria to case and controls may result
in more homogeneous subject thereby enhancing power.
Powerful GWA scans
arcOGEN stage 1 and 2
At the OARSI 2011 the arcOGEN phase 2 meta analysis results
were reported based onworld wide OA studies containing a total of
7,410 knee and/or hip OA cases and 11,009 controls as follow-up of
the ﬁrst phase1. In total ﬁve loci showed association at the genome-
wide signiﬁcance threshold (P< 5108) albeit for different
phenotypic OA strata: all combined, knee only, hip only, only in
men or women. Since stratiﬁcation by deﬁnition consumes power,
this differentiated result typically reﬂects the clinical and genetic
heterogeneity of the OA phenotype. Themost highly associated SNP
was found in the total joint replacement (TJR) analysis (P-val-
ue¼ 7.21011) for an SNP located at chr3p21.1, in a region
encompassing a large number of genes. The other genome-wide
signiﬁcant signals were found at chromosomal regions containing
genes with no known role in OA with the exception of a variant in
CHST11 (chondroitin 4 sulfotransferase 11) gene associated with
total hip replacement. This gene is reported to be important for
chondrocyte development during cartilage morphogenesis14.
Although, substantial efforts are necessary to elucidate the under-
lying mechanisms of the discovered unknown OA susceptibility
genes, they may provide new compelling insights in how OA arises.
arcOGEN 1000 genomes imputation
Recently, through a large scale next generation sequencing
effort, the whole genome sequence of individuals of Caucasian
origin have become publicly available15. This dataset can be used to
infer a large numbers of additional genotypes in GWA studiesthrough the identiﬁcation of coinheritance patterns (haplotypes)
on which low frequency SNPs reside. The application of these
imputations to the OA genetic research holds the potential to
discover genes and their rare variants that explain a much larger
part of the heritability. Day-Williams et al.16 reported on a genome
wide signiﬁcant result of SNP rs11842874 (minor allele frequency
w0.07) with a combined odds ratio of 1.17 (95% conﬁdence interval
(CI) of 1.11e1.23) with P-value 2.13108 within the MCF2L gene
(MCF.2 cell-line-derived transforming sequence-like, encoding the
guanine nucleotide exchange factor) which was found to be asso-
ciated across a total of 19,041 OA cases and 24,504 controls of
European descent. Although the SNP was already present on the
original genotyping array, the MCF2L OA locus was taken forward
on the basis of evidence accrued through imputation based on the
1000-genomes dataset which could not be observedwith the initial
imputation based on HapMap data. In human cells,MCF2L regulates
neurotrophin-3-induced cell migration in Schwann cells, is
a member of the nerve growth factor (NGF) family and is antici-
pated to play a role in OA through modulation of pain perception16.
The Rotterdam GWA study on joint space width (JSW)
Another possible enhanced use of GWA studies could be to
explore the case distribution towards endophenotypes that repre-
sent different aspects of the complex OA disease phenotype as
opposed to the traditional binomial distribution of cases and
controls. A compelling example was presented at OARSI 2011 by
Castano Betancourt et al.17 concerning a genome wide association
scans (GWAS) on quantitatively assessed minimal joint space width
(mJSW) of the hip radiographs in a discovery sample of 6,523
participants from the Rotterdam Study I and II and with subsequent
replication in a total of 4,443 individuals from three studies in the
UK (Chingford, GOAL and TwinsUK). In the discovery cohort an SNP
on chromosome 19 was found to be associated with JSW differ-
ences which replicated in an overall meta-analysis with a genome
wide signiﬁcant P value of 1.11011. The minor allele, that asso-
ciated with a larger joint space, was also associated with
a decreased risk for hip OA (P-value¼ 7105) and consistently
associated with mJSW in individuals without hip OA, suggesting
that the effect is on cartilage thickness rather than degradation. The
SNP is located in a gene that has recently been linked to Wnt-
signaling, and these results now suggest a role in chondrogenic
differentiation.
This example may soon be followed by other promising quan-
titative traits such as statistical shape models determining aspects
of e.g., hip shape18 or biochemical marker levels. Such analyses will
additionally contribute to the understanding of pleiotropic aspects
of OA as complex disease.
Candidate gene studies
COL11A1
Potential possibilities of these large consortia are to rerun
dedicated analyses for a limited number of genes which e.g.,
represent a pathway likely to be involved in OA pathophysiology. A
major advantage is that such a gene set analyses does not suffer
from the penalty of performing over amillion tests which applies to
genome wide analyses. At OARSI 2011 Rodriguez-Fontela et al.19
and Kerkhof et al.20 each reported on gene set screen by means of
a meta analysis across eight GWAS of the TREATwOA consortium
with respectively, OA susceptibility genes and genes that are found
to cause rare skeletal (dysplasia) syndromes. OA susceptibility
genes were identiﬁed by a systemic screen in the HUGE Navigator
with search terms OA, spinal osteophytosis and intervertebral disk
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OA candidate genes. The skeletal dysplasia genes were selected
from the international ontology and classiﬁcation of skeletal
disorders and from the Online Mendelian Inheritance in Man
(OMIM) database resulting in a set of 2,766 independent SNPs
across 142 genes. For the COL11A1 gene which was overlapping in
the gene sets both studies observed a signiﬁcant overlapping
association with hip OA (P-value for both analyses w105) albeit
with two independent SNPs that were not in linkage disequilib-
rium. COL11A1 is a minor ﬁbrillar collagenwhich adds structure and
strength to connective tissue and this collagen was also previously
identiﬁed as potential OA susceptibility gene through the arcOGEN
stage 1 GWA1. Despite the fact that the identiﬁed SNPs were not in
linkage disequilibrium (LD) it should be noted that the three studies
contain overlapping cases and controls and these associations may
partly reﬂect the same signal. Irrespectively, these evidences could
be considered a revival of COL11A1 as OA susceptibility gene and
may justify additional investigation.
HLA locus on chromosome 6p
In 2010, a Japanese GWA study in 899 cases and 3,396 controls
reported on two SNPs, located in a small region of the HLA locus,
that associated to knee OA (Table II)21. Although this initial result in
Japanese subjects reached genome wide signiﬁcance (P-value of
6.7108), the association appeared absent in a relative small
European sample21. Subsequently, Shi et al.22 reported on the
absence of association in Han Chinese and more recently, a large
scale European replication study also showed absence of associa-
tion of the two SNPs across in 36,408 controls and 5,749 knee OA
cases of European descent22. In the latter study, it was also shown
that differences in linkage disequilibrium across the locus may be
a possible explanation for this lack of replication23.
Functional follow up
Growth differentiation factor 5 (GDF5)
In early 2011, Daans et al.24 reported on the haplo-insufﬁcient
GDF5 mice which didn’t show developmental abnormalities,
however, the genotype was shown to confer an increased risk to
develop OA upon joint integrity challenges indicating for the ﬁrst
time in OA that subtle changes in gene expression in the target
tissue throughout life could predispose to OA onset. Moreover, in
2011 the previously assessed imbalanced allelic expression of GDF5
in human joint tissues25 was functionally explored in a study by
Reynard et al.26. This study demonstrated that the differential allelic
expression was modulated epigenetically by CpG sites in the
promoter of the GDF5 gene. Subsequently, it was shown that the
CpG sites formed by the presence of the C alleles at the suscepti-
bility SNPs rs143383 and rs143384 were variably methylated and
that treatment of a heterozygous cell line with a demethylatingTable II
Updated list of recent OA susceptibility loci discovered by a combination of GWA
a candidate gene approaches
Phenotype Pathway involved Reference
Candidate gene
COL11A1 Hip OA ECM matrix 18,19
GWA
Chrom 19 JSW Cartilage morphogenesis 16
MCF2L Knee or hip OA Pain perception 15
Chrom 3p21.1 TJR e 14
CHST11 Hip OA Cartilage morphogenesis 14
Chrom¼ chromosome.agent further increased the allelic expression imbalance between
the C and T alleles. This study demonstrates compelling evidence
that the genetic effect of the rs143383 SNP on GDF5 expression is
modulated epigenetically by DNA methylation. The variability in
the allelic expression balance of rs143383 is therefore partly
accounted for by differences in DNA methylation, which in turn
may inﬂuence the penetrance of this allele in susceptibility to
common musculoskeletal diseases.
Chromosome 7q22 locus
The 7q22 locus contains six known genes in a linkage disequi-
librium block extending over 500 kb: PRKAR2B, encoding protein
kinase-cAMP-dependent-regulatory-type II-b; HPB1, encoding
HMG-box transcription factor 1; COG5, encoding component of
oligomeric golgi complex 5; GPR22, encoding an orphan G protein-
coupled receptor 22; DUS4L, encoding dihydrouridine synthase
4-like and BCAP29, encoding B-cell receptor-associated protein 29
and none of these genes qualiﬁes as an obvious OA candidate but all
are expressed to lower or higher extent in either healthy or OA
affected cartilage. At the OARSI 2011 results were presented on
relevant functional aspects of the GPR22 locus in the mouse
chondrogenic cell line ATDC5. The authors concluded that GPR22
plays a critical role in the fate of chondrogenic cells and points
towards the hypertrophic switch observed in articular chon-
drocytes in the course of OA27.
Together the functional studies on GDF5 and GPR22 conﬁrm the
generally accepted expectation that imbalanced allelic expression
and/or gene expressionmay be an importantmolecularmechanism
underlying genetic predisposition of complex traits28.
Promise for 2012
As indicated in this review the major promise for 2011, being
the generation of robust signals in GWA studies by the use of large
numbers of cases and controls, are currently being granted. Details
of these studies will most likely be published in the next 6 months
and OA susceptibility SNPs within new genes and pathways will be
elucidated. However, another part of these SNPs may be unknown,
not be previously associated to OA, not be disease speciﬁc nor even
be expressed in joint tissues. Efforts to uncover such novel players
and to elucidate mechanisms of current OA susceptibility genes
and pathways demands extensive functional genomic research
(DNA and RNA) to relevant joint tissue (affected and preserved
cartilage, subchondral bone, osteophytes ligaments), cell models
(e.g., modulations of GPR22 expression in ATDC5 cells during
chondrogenesis) and animal models (haplo-insufﬁcient GDF5
mouse model).
Given the speciﬁc GWA approach taken, the identiﬁed SNPs will
onlyhave small effect sizes and therefore addonly slightly to the total
attributable genetic risk of OA. As with other complex diseases
a major challenge that remains is to explain this so called “missing
part” of the heritability. Hopes are high for deep sequencing
approaches byapplyingnext generation sequencing (whole genome,
exome, and RNA-sequencing) to uncover additional rare genetic
variation speciﬁc to OA susceptibility that may ﬁll-in some of the
heritability gap. We should, however, be aware that these
approaches have, thus far, been successful mainly for disease gene
discovery in more monogenic disorders resulting from private
mutations with high penetrance29. Meanwhile, many efforts are
undertaken to adapt the next generation sequencing approaches by
exploring the extent to which rare alleles explain the heritability by
means of calculating burden of rare variants in respective genes or
genes in a pathways. A lot of work is, however, lying ahead to over-
come the obvious power issues that such approaches suffer from30.
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